Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Scientists finally uncover why statins can cause muscle pain | ScienceDaily (opens in a new tab)

sciencedaily.com · 2026-10-20

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

3 claims go further than the study. One other point was not covered by the paper.

  • 1 supported
  • 3 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Three of five claims overstate the study. One of five checks out. One claim the study doesn't address.

  • 1 supported
  • 3 overstated
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedScientists have uncovered a surprising reason why statins can sometimes cause muscle pain, weakness, and even severe muscle damage.View evidenceHide evidence

As statedsometimes; a small number; millions of users

Why this verdict

The abstract-level profile supports a molecular off-target interaction between atorvastatin and RyR1, plus a structural model in which atorvastatin binding is associated with RyR1 opening. But the headline frames this as an uncovered reason why statins cause clinical muscle pain, weakness, and severe muscle damage. The supplied paper profile is basic structural work and does not, at abstract depth, provide direct clinical evidence that this mechanism causes those patient outcomes. The headline therefore outruns the evidence and the story’s own more mechanistic body framing.

1

Study evidence

Authors report cryo-EM structures of RyR1 both without and with atorvastatin and conclude that RyR1 directly binds atorvastatin.

“Here we report cryo-EM structures of RyR1 in the absence and presence of atorvastatin, firmly establishing RyR1 as an unintended off-target.”
2

Study evidence

One atorvastatin molecule per RyR1 subunit can bind a transmembrane region of closed RyR1 and induce small structural perturbations interpreted as priming the channel for opening.

“Atorvastatin activates RyR1 in a sequential way, whereby one statin per subunit can bind to the transmembrane region of a closed RyR1, with small structural perturbations that prime the channel for opening.”
Claim 2 of 5OverstatedUsing cryo-electron microscopy, the researchers found that statins can bind to the ryanodine receptor (RyR1) in muscle cells and force the channel open, causing calcium to leak continuously and potentially damage muscle tissue.View evidenceHide evidence

As statedcontinuously

Why this verdict

The paper profile supports use of cryo-EM and supports atorvastatin binding to RyR1, with additional atorvastatin binding associated with pVSD widening and pore opening. However, the story’s wording is stronger than the profile: it says statins generally can bind RyR1, 'force' the channel open, cause calcium to leak 'continuously,' and potentially damage muscle tissue. The abstract-level profile does not report direct functional calcium-leak assays, continuous leak measurements, or tissue-damage experiments; it describes a structural, inferential activation model for atorvastatin.

1

Study evidence

Authors report cryo-EM structures of RyR1 both without and with atorvastatin and conclude that RyR1 directly binds atorvastatin.

“Here we report cryo-EM structures of RyR1 in the absence and presence of atorvastatin, firmly establishing RyR1 as an unintended off-target.”
2

Study evidence

One atorvastatin molecule per RyR1 subunit can bind a transmembrane region of closed RyR1 and induce small structural perturbations interpreted as priming the channel for opening.

“Atorvastatin activates RyR1 in a sequential way, whereby one statin per subunit can bind to the transmembrane region of a closed RyR1, with small structural perturbations that prime the channel for opening.”
Claim 3 of 5OverstatedThe story says the discovery could guide development of safer statins or other cholesterol drugs that preserve cholesterol-lowering benefits while minimizing muscle-related side effects.View evidenceHide evidence

Why this verdict

The profile supports the narrower idea that structural comparison of atorvastatin binding to RyR1 versus HMG-CoA reductase offers clues for modifying statins to reduce RyR1 binding while preserving intended target binding. The story is directionally aligned but broadens this to development of safer statins or other cholesterol drugs and to minimizing muscle side effects. The abstract-level profile describes inferential design clues, not validated redesigned drugs or demonstrated side-effect reduction.

1

Study evidence

Comparative structural analysis indicates specific differences between the RyR1 atorvastatin binding mode and the HMG‑CoA reductase atorvastatin binding mode; these differences are proposed as actionable clues for chemical modification of atorvastatin to reduce RyR1 off‑target binding while retaining HMG‑CoA reductase binding.

“Comparison with atorvastatin binding to HMG-CoA reductase, its intended target, offers clues on how to modify the statin to reduce RyR1 binding, while leaving binding to HMG-CoA reductase unperturbed.”
Claim 4 of 5Not coveredThe article says atorvastatin was the main focus, but suggests similar interactions could occur with other statins.View evidenceHide evidence

Why this verdict

The profile clearly indicates that atorvastatin is the studied ligand. It does not provide abstract-level evidence that other statins were tested or that similar RyR1 interactions occur across the statin class. The suggestion may be plausible, but it is not verifiable from the supplied abstract-depth paper profile.

1

Study evidence

Authors report cryo-EM structures of RyR1 both without and with atorvastatin and conclude that RyR1 directly binds atorvastatin.

“Here we report cryo-EM structures of RyR1 in the absence and presence of atorvastatin, firmly establishing RyR1 as an unintended off-target.”
2

Study evidence

One atorvastatin molecule per RyR1 subunit can bind a transmembrane region of closed RyR1 and induce small structural perturbations interpreted as priming the channel for opening.

“Atorvastatin activates RyR1 in a sequential way, whereby one statin per subunit can bind to the transmembrane region of a closed RyR1, with small structural perturbations that prime the channel for opening.”
Claim 5 of 5SupportedResearchers at the University of British Columbia, working with colleagues at the University of Wisconsin-Madison, identified a molecular mechanism that may explain statin-related muscle complications, and they say their findings were published in Nature Communications.View evidenceHide evidence

Why this verdict

The core scientific claim is supported: the profile says the paper reports cryo-EM structures showing atorvastatin binding to RyR1 and interprets these structures as a sequential activation mechanism that may explain statin-related muscle complications. The supplied profile does not independently verify affiliations or publication venue metadata, but the mechanism claim itself is consistent with the abstract-level evidence.

1

Study evidence

Authors report cryo-EM structures of RyR1 both without and with atorvastatin and conclude that RyR1 directly binds atorvastatin.

“Here we report cryo-EM structures of RyR1 in the absence and presence of atorvastatin, firmly establishing RyR1 as an unintended off-target.”
2

Study evidence

One atorvastatin molecule per RyR1 subunit can bind a transmembrane region of closed RyR1 and induce small structural perturbations interpreted as priming the channel for opening.

“Atorvastatin activates RyR1 in a sequential way, whereby one statin per subunit can bind to the transmembrane region of a closed RyR1, with small structural perturbations that prime the channel for opening.”
Then look for missing context

Context layer

What the story carried across

Nothing material from the study was dropped.

4 things the story did carry across
  • The paper reports cryo-EM structures of RyR1 without and with atorvastatin, establishing RyR1 as an unintended off-target and showing three atorvastatin molecules binding in a pVSD cleft.
  • The paper’s proposed mechanism is a sequential, occupancy-dependent structural activation model: one atorvastatin per subunit primes closed RyR1, and additional atorvastatin molecules are associated with pVSD widening and pore opening.
  • The paper compares atorvastatin binding at RyR1 with HMG-CoA reductase to infer possible redesign principles for reducing RyR1 off-target binding while preserving intended target binding.
  • No experimentally validated redesigned statins or tested analogs are described in the abstract-level profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroDetermine whether the skeletal muscle ryanodine receptor (RyR1) directly binds atorvastatin and define the structural basis (including the reported statin “triplet” binding mode).single-particle cryo-EM structure determinationExpand

In plain English

The paper reports single-particle cryo-EM structures of skeletal muscle RyR1 in the absence and presence of atorvastatin. Structures show three atorvastatin molecules binding together in a cleft formed by the pseudo-voltage sensing domain (pVSD). The authors describe a sequential binding model in which one statin per subunit binds to a closed RyR1 with small perturbations that prime the channel, and binding of two additional statins per subunit is associated with pVSD widening that triggers pore opening. The structures are compared with atorvastatin binding to HMG-CoA reductase to suggest routes to reduce RyR1 binding while preserving the intended target interaction.

Key findings

  • Authors report cryo-EM structures of RyR1 both without and with atorvastatin and conclude that RyR1 directly binds atorvastatin.
  • Three atorvastatin molecules bind together in a cleft formed by the pseudo-voltage sensing domain (pVSD), forming an unusual ‘triplet’ binding mode.
“Here we report cryo-EM structures of RyR1 in the absence and presence of atorvastatin, firmly establishing RyR1 as an unintended off-target.”
What this piece can’t prove
  • Abstract does not report independent biochemical/biophysical affinity measurements or functional assays within the quoted spans to corroborate the structural interpretation of activation.

2 further details could not be confirmed from the summary.

2in vitroExplain the sequential mechanism by which atorvastatin binding primes and then opens RyR1 (closed-to-open gating-associated structural transitions).multi-state single-particle cryo-EM / heterogeneity analysisExpand

In plain English

Cryo-EM structures of RyR1 in the absence and presence of atorvastatin are reported and interpreted as a sequential, occupancy-dependent activation mechanism: one atorvastatin molecule per subunit can bind a transmembrane region of closed RyR1 producing small structural perturbations that 'prime' the channel, and binding of two additional atorvastatin molecules per subunit is associated with widening of the pseudo-voltage sensing domain (pVSD) and opening of the pore.

Key findings

  • One atorvastatin molecule per RyR1 subunit can bind a transmembrane region of closed RyR1 and induce small structural perturbations interpreted as priming the channel for opening.
  • Binding of two additional atorvastatin molecules per subunit is associated with widening of the pseudo-voltage sensing domain (pVSD) and with opening of the pore.
“Atorvastatin activates RyR1 in a sequential way, whereby one statin per subunit can bind to the transmembrane region of a closed RyR1, with small structural perturbations that prime the channel for opening.”
What this piece can’t prove
  • Conclusions rely on state separation and ligand-occupancy assignment from cryo-EM reconstructions; the abstract does not provide details on resolution, classification robustness, or occupancy validation.
  • Mechanistic claims (priming → opening) are inferred from structural correlations across states; the abstract does not report direct functional measurements linking the observed structural states to channel activity.

1 further detail could not be confirmed from the summary.

3in silicoCompare atorvastatin binding at RyR1 versus its intended target HMG-CoA reductase to infer principles for redesigning statins that reduce RyR1 off-target binding while preserving on-target binding.in silico structural comparisonExpand

In plain English

The authors compare cryo-EM–resolved atorvastatin binding to RyR1 (three atorvastatin molecules per cleft) with published atorvastatin–HMG‑CoA reductase complexes and infer structural differences that could guide chemical modifications to reduce RyR1 off-target binding while preserving on-target HMG‑CoA reductase binding.

Key findings

  • Comparative structural analysis indicates specific differences between the RyR1 atorvastatin binding mode and the HMG‑CoA reductase atorvastatin binding mode; these differences are proposed as actionable clues for chemical modification of atorvastatin to reduce RyR1 off‑target binding while retaining HMG‑CoA reductase binding.
“Comparison with atorvastatin binding to HMG-CoA reductase, its intended target, offers clues on how to modify the statin to reduce RyR1 binding, while leaving binding to HMG-CoA reductase unperturbed.”
What this piece can’t prove
  • Appraisal relies on the abstract description; the full paper may contain more detailed methods or validation not visible here.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 37 candidate papers

And 31 more candidates considered.